Intellia Therapeutics (NTLA) Receivables - Other (2015 - 2023)

Intellia Therapeutics (NTLA) has reported Receivables - Other for 9 consecutive years, with $1.0 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Receivables - Other fell 37.5% year-over-year to $1.0 million; the TTM figure through Dec 2023 stood at $1.0 million (down 37.5% YoY), while the FY2023 annual figure was $1.0 million, down 37.5% from the prior year.
• Receivables - Other held at $1.0 million in Q4 2023 per NTLA's latest filing, from $1.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $8.4 million in Q1 2020 and bottomed at $700000.0 in Q1 2023.
• Historically, Receivables - Other has averaged $2.2 million across 5 years, with a median of $1.5 million in 2022.
• Annual changes were most pronounced in 2020 — Receivables - Other surged 740.0% — and 2021, when it tumbled 88.1%.
• Intellia Therapeutics' Receivables - Other stood at $3.6 million in 2019, then sank by 41.67% to $2.1 million in 2020, then changed by 0.0% to $2.1 million in 2021, then dropped by 23.81% to $1.6 million in 2022, then plunged by 37.5% to $1.0 million in 2023.
• Business Quant data shows NTLA's Receivables - Other at $1.0 million in Q4 2023, $1.0 million in Q3 2023, and $1.4 million in Q2 2023.